A Phase 2 interventional study of Astegolimab and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Genentech, Inc.. Completed at 193 sites in 24 countries. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is one of 2 that started in 2021, is one of 4 in phase 2, and was the 4th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 2
First in 2009; this study’s year is marked. 2 started in 2021.
This study's enrollment of 1,334 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 104 across the 9 interventional studies, 0 across the 1 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).
Drug: Astegolimab
Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).
Drug: Astegolimab
Participants will receive SC placebo Q2W.
Drug: Placebo
Participants will receive SC astegolimab Q2W or Q4W.
Participants will receive SC placebo Q2W.
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.
Time frame: Baseline up to Week 52
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL)
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that led to hospitalization (duration \> 24 hours) or death. Unadjusted AER was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values are reported. Number analyzed is the number of participants with data available for analysis.
Time frame: Baseline to Week 52
Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period
Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation is defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \> 10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation is defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. Kaplan-Meier (K-M) method was used to estimate the median time.
Time frame: Baseline up to Week 52
Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score
SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean of change from baseline (CFB) is reported here.
Time frame: At Week 52
Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total Score
Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.
Time frame: At Week 52
Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52
Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. This analysis used a MMRM model. Adjusted mean of CFB is reported here.
Time frame: At Week 52
Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52
EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess frequency, severity, \& duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. This analysis used a MMRM model. Adjusted mean of CFB has been reported here.
Time frame: At Week 52
Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period
A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.
Time frame: Baseline up to Week 52
Absolute Change From Baseline in Five-repetition Sit-to-stand (5STS) Time (Seconds) at Week 52
The 5STS was used to assess the time taken to stand up from a seated position five times, in as rapid succession as possible. The functional test related strongly to lower limb function and frailty in participants with COPD; an inability to perform a single sit-to-stand or to complete five repeat sit-to-stands within 60 seconds denoted an inability to perform the test. This analysis used a MMRM model. Adjusted mean values have been reported.
Time frame: At Week 52
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to 98.1 weeks
Main Study: Serum Concentrations of Astegolimab at Specified Timepoints
PK samples in the main study were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.
Time frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 52 and 62 (SFU); Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
Intensive PK Sampling Substudy: Serum Concentrations of Astegolimab at Specified Timepoints
PK samples in the intensive PK sampling substudy were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.
Time frame: Period 1: Pre-dose on Day 1 of Week 1 and at Weeks 4, 12, 24, 36, 48, 52, and 62 (SFU), Post-dose on Days 3, 7, and 10 of Week 1, Day 7 of Week 48, Day 28 post-dose from Week 52; Period 2: Pre-dose at Weeks 52, 64, 76, 88, and 98 (SFU)
Number of Participants With Anti-drug Antibodies (ADAs) to Astegolimab
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
Time frame: Up to 98.1 weeks
A total of 1334 participants with chronic obstructive pulmonary disease (COPD) who were former or current smokers and had a history of frequent exacerbations took part in the study at 191 investigative sites across 24 countries from 05 October 2021 to 07 July 2025.
| Milestone | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Started | 443 | 447 | 444 |
| Safety-evaluable (se) population | 449 | 442 | 442 |
| Completed | 372 | 376 | 375 |
| Not completed | 71 | 71 | 69 |
| Withdrew: Adverse event | 15 | 11 | 13 |
| Withdrew: Death | 11 | 7 | 13 |
| Withdrew: Lack of efficacy | 3 | 4 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 0 |
| Withdrew: Reason not specified | 2 | 1 | 1 |
| Withdrew: Physician decision | 1 | 4 | 1 |
| Withdrew: Protocol deviation | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 37 | 39 | 39 |
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.
| exacerbations per patient-year | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period | 1.110 | 1.222 | 1.315 |
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that led to hospitalization (duration \> 24 hours) or death. Unadjusted AER was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values are reported. Number analyzed is the number of participants with data available for analysis.
| exacerbations per patient-year | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-Week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (< 300 Cells/uL) | 1.123 | 1.206 | 1.295 |
Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation is defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \> 10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation is defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. Kaplan-Meier (K-M) method was used to estimate the median time.
| weeks | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Time to First Moderate or Severe COPD Exacerbation During the 52-Week Treatment Period | 42.4 (30.1 to NA) | 39.9 (31.1 to 46.1) | 33.7 (27.4 to 44.3) |
SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. This analysis used a Mixed Model for Repeated Measurements (MMRM) model. Adjusted mean of change from baseline (CFB) is reported here.
| score on a scale | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score | -6.691 ± 0.767 | -6.383 ± 0.762 | -4.888 ± 0.769 |
Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.
| percentage of participants | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed Through SGRQ-C Total Score | 54.31 | 54.28 | 49.78 |
Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. This analysis used a MMRM model. Adjusted mean of CFB is reported here.
| liters | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52 | -0.003 ± 0.012 | -0.001 ± 0.011 | -0.017 ± 0.012 |
EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess frequency, severity, \& duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. This analysis used a MMRM model. Adjusted mean of CFB has been reported here.
| score on a scale | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) Total Score at Week 52 | -1.247 ± 0.299 | -1.318 ± 0.299 | -1.117 ± 0.298 |
A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or lead to death. The unadjusted annual exacerbation rate (AER) was estimated as the total number of moderate and severe COPD exacerbations over the treatment period divided by the total patient-years at risk. The time at risk (in years) was the number of days from the date of first administration of study drug to the date of study completion or discontinuation in the 52-week treatment period, divided by 365.25 days. The adjusted AER was estimated using a negative binomial regression model. Adjusted rate values have been reported.
| exacerbations per patient-year | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period | 0.182 | 0.198 | 0.255 |
The 5STS was used to assess the time taken to stand up from a seated position five times, in as rapid succession as possible. The functional test related strongly to lower limb function and frailty in participants with COPD; an inability to perform a single sit-to-stand or to complete five repeat sit-to-stands within 60 seconds denoted an inability to perform the test. This analysis used a MMRM model. Adjusted mean values have been reported.
| seconds | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Five-repetition Sit-to-stand (5STS) Time (Seconds) at Week 52 | -1.946 ± 0.411 | -1.669 ± 0.411 | -1.625 ± 0.413 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 367 | 370 | 386 |
PK samples in the main study were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.
| micrograms per milliliter (µg/mL) | Astegolimab Q2W | Astegolimab Q4W |
|---|---|---|
| Period 1: Pre-dose on Day 1 of Week 1 | NA ± NA | NA ± NA |
| Period 1: Pre-dose at Week 4 | 72.2 ± 69.4 | 32.1 ± 73.2 |
| Period 1: Pre-dose at Week 12 | 119 ± 59.9 | 54.0 ± 60.8 |
| Period 1: Pre-dose at Week 24 | 124 ± 104.1 | 55.8 ± 97.5 |
| Period 1: Pre-dose at Week 36 | 127 ± 118.5 | 54.4 ± 110.4 |
| Period 1: At Week 52 | 123 ± 162.6 | 49.3 ± 127.4 |
| Period 1: At Week 62 (SFU) | 12.6 ± 734.8 | 3.04 ± 764.2 |
| Period 2: Pre-dose at Week 52 | 107 ± 196.5 | 50.4 ± 158.8 |
| Period 2: Pre-dose at Week 64 | 100 ± 170.5 | 54.1 ± 182.4 |
| Period 2: Pre-dose at Week 76 | 87.8 ± 416.3 | 43.7 ± 333.6 |
| Period 2: Pre-dose at Week 88 | 128 ± 37.4 | 85.3 ± 113.0 |
| Period 2: Pre-dose at Week 98 (SFU) | 8.60 ± 161.8 | 25.8 ± 48.3 |
PK samples in the intensive PK sampling substudy were collected during the 52-week double-blinded treatment period (Period 1), additional blinded treatment period (Period 2), and SFU period.
| µg/mL | Astegolimab Q2W | Astegolimab Q4W |
|---|---|---|
| Period 1: Pre-dose on Day 1 of Week 1 | NA ± NA | NA ± NA |
| Period 1: Post-dose on Day 3 of Week 1 | 40.0 ± 248.8 | 40.6 ± 173.5 |
| Period 1: Post-dose on Day 7 of Week 1 | 49.8 ± 173.2 | 55.2 ± 44.9 |
| Period 1: Post-dose on Day 10 of Week 1 | 41.0 ± 229.8 | 43.9 ± 152.0 |
| Period 1: Pre-dose at Week 4 | 77.9 ± 110.4 | 30.7 ± 46.8 |
| Period 1: Pre-dose at Week 12 | 124 ± 126.8 | 54.2 ± 60.8 |
| Period 1: Pre-dose at Week 24 | 131 ± 131.8 | 62.1 ± 58.7 |
| Period 1: Pre-dose at Week 36 | 120 ± 166.7 | 61.5 ± 61.7 |
| Period 1: Pre-dose at Week 48 | 129 ± 174.2 | 55.8 ± 62.8 |
| Period 1: Day 7 of Week 48 | 150 ± 151.2 | 98.8 ± 46.8 |
| Period 1: Pre-dose at Week 52 | 40.3 ± 3239.4 | 54.5 ± 65.9 |
| Period 1: Day 28 Post-dose From Week 52 | 2.87 ± NA | 24.5 ± 120.2 |
| Period 1: Pre-dose at Week 62 (SFU) | 2.02 ± NA | 5.32 ± 247.7 |
| Period 2: Pre-dose at Week 52 | 161 ± 39.5 | 57.2 ± 59.1 |
| Period 2: Pre-dose at Week 64 | 146 ± 32.6 | 59.2 ± 53.3 |
| Period 2: Pre-dose at Week 76 | 147 ± 43.1 | 54.3 ± 57.7 |
| Period 2: Pre-dose at Week 88 | 142 ± 43.6 | 103 ± 103.4 |
| Period 2: Pre-dose at Week 98 (SFU) | — | 1.13 ± NA |
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.
| Participants | Astegolimab Q2W | Astegolimab Q4W |
|---|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to Astegolimab | 4 | 5 |
Collected over Up to 98.1 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Astegolimab Q2W | 13/449 (2.9%) | 111/449 (24.7%) | 272/449 (60.6%) |
| Astegolimab Q4W | 11/442 (2.5%) | 126/442 (28.5%) | 285/442 (64.5%) |
| Placebo | 16/442 (3.6%) | 137/442 (31%) | 281/442 (63.6%) |
| Event | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 64/449 | 71/442 | 71/442 |
| PneumoniaInfections and infestations | 15/449 | 11/442 | 9/442 |
| Atrial fibrillationCardiac disorders | 1/449 | 1/442 | 5/442 |
| COVID-19Infections and infestations | 2/449 | 4/442 | 5/442 |
| Acute kidney injuryRenal and urinary disorders | 2/449 | 5/442 | 0/442 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/449 | 3/442 | 4/442 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/449 | 1/442 | 3/442 |
| Cholecystitis acuteHepatobiliary disorders | 0/449 | 3/442 | 1/442 |
| SepsisInfections and infestations | 0/449 | 3/442 | 2/442 |
| Rib fractureInjury, poisoning and procedural complications | 0/449 | 0/442 | 3/442 |
| Event | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 226/449 | 238/442 | 237/442 |
| NasopharyngitisInfections and infestations | 52/449 | 47/442 | 37/442 |
| COVID-19Infections and infestations | 30/449 | 40/442 | 31/442 |
| Injection site reactionGeneral disorders | 20/449 | 30/442 | 27/442 |
| Back painMusculoskeletal and connective tissue disorders | 18/449 | 26/442 | 23/442 |
| HypertensionVascular disorders | 20/449 | 24/442 | 24/442 |
| Urinary tract infectionInfections and infestations | 18/449 | 15/442 | 23/442 |
Intent-to-treat (ITT) population included all randomized participants, whether or not the participant received the assigned treatment, with participants grouped according to the treatment assigned at randomization.
| Age, Customized(Participants) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| Adults (18-64 Years) | 176 | 151 | 146 | 473 |
| From 65-84 Years | 261 | 294 | 294 | 849 |
| 85 Years and Over | 6 | 2 | 4 | 12 |
| Sex: Female, Male(Participants) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| Female | 187 | 199 | 202 | 588 |
| Male | 256 | 248 | 242 | 746 |
| Ethnicity (NIH/OMB)(Participants) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 82 | 78 | 84 | 244 |
| Not Hispanic or Latino | 352 | 361 | 346 | 1059 |
| Unknown or Not Reported | 9 | 8 | 14 | 31 |
| Race (NIH/OMB)(Participants) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 1 | 8 | 14 |
| Asian | 6 | 10 | 10 | 26 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 1 | 4 |
| Black or African American | 9 | 12 | 15 | 36 |
| White | 405 | 406 | 400 | 1211 |
| More than one race | 8 | 8 | 8 | 24 |
| Unknown or Not Reported | 9 | 8 | 2 | 19 |
Showing the first 100 of 193 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Oct 2021 to primary completion in Feb 2025, 40 months.
Results were first posted in Oct 2026, 1 year 7 months after primary completion. A results delay was requested in Feb 2026.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 40 months is above that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Astegolimab
Pulmonary Disease, Chronic Obstructive →